核心观点公司的ASC30 和ASC47 两款药物亮相ADA 大会,产品后续前景值得关注。其中,ASC30 的SAD 研究表明其具备良好的药动学特征以及长半衰期,产品成药性好,同时药物安全性良好,主要副作用为轻中度。ASC47 的研究结果表明其在临床前动物模型中具备减脂增肌和降体重效果,后续人体结果值得期待。综上我们认为,公司的创新管线临床持续推进,各项研究结果均表明产品具备好的成药性和安全型基础,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.